Company news
Shanghai Yizhong Pharmaceutical Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
November 4, 2026
(688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Report for Q3 2026
October 27, 2026
(688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Resolutions of the 7th Meeting of the 3rd Board of Directors
October 27, 2026
(688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Completion of First Dosing in the First Dose Cohort of the Phase I Clinical Trial of Innovative Drug YXC-001
October 21, 2026
(688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Implementation Results of Share Repurchase and Share Changes
October 19, 2026
(688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares
October 9, 2026
Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
August 28, 2026
Announcement on the Grant of Reserved Restricted Shares to Participants under the 2026 Restricted Share Incentive Plan
August 25, 2026
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial for the Investigational Innovative Drug YXC-002
August 18, 2026
Voluntary Disclosure Announcement on Receipt of a Notice of Approval for Drug Clinical Trial for the Investigational Innovative Drug YXC-001
August 17, 2026
Announcement on the Company and Its Wholly-owned Subsidiaries Using Certain Idle Raised Funds for Cash Management
August 6, 2026
Announcement on Progress in Repurchasing Shares
August 3, 2026
Announcement on Shareholding Increase by the Actual Controller
July 30, 2026
Announcement on Cumulative Repurchase of 1% Shares through Call Auction and Progress of Share Repurchase
July 28, 2026
Announcement on Initial Repurchase of Shares through Call Auction
July 21, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
July 17, 2026
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase
July 13, 2026
Review Opinion and Statement on the Public Disclosure of the List of Participants under the Company's 2026 Restricted Share Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors
July 12, 2026
Announcement on the Shareholdings of the Top Ten Shareholders and the Top Ten Holders of Unrestricted Shares Prior to the Share Repurchase
July 7, 2026
Announcement on Resolutions of the 3rd Meeting of the 3rd Board of Directors
July 1, 2026
Announcement on the Proposal by Actual Controller and Chairman to Repurchase the Shares
June 24, 2026
Announcement on Early Termination of Current Plan for Sale of Repurchased Shares and Results of the Share Sale
June 15, 2026
Announcement on Voluntary Disclosure on the Acceptance of the Clinical Trial Application for the Investigational New Drug YXC-002
June 10, 2026
Announcement on Result of Shareholding Reduction by Shareholders
June 2, 2026
Announcement on Progress in Sale of Repurchased Shares
June 1, 2026
Announcement on Election of Employee Director
May 27, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 22, 2026
Announcement on Resolutions of the 16th Meeting of the 2nd Board of Directors
May 20, 2026
Announcement on Renewing Engagement of Accounting Firm
April 27, 2026
Indicative Announcement on Changes in Shareholder Equity Reaching Integer Multiple of 1%
April 2, 2026
Announcement on Initial Sales of the Company's Shares through Call Auction
April 1, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 2, 2026
Announcement on Progress Regarding the Sale of Repurchased Shares
February 1, 2026
Announcement on Shareholding Reduction Plan for Shareholders
January 30, 2026
Announcement on Earnings Preannouncement for 2025
January 21, 2026
Announcement on Plan to Sell Repurchased Shares in 2024 through Call Auction
December 29, 2025
Announcement on Result of Shareholding Reduction by Shareholder
November 26, 2025
Announcement on Implementation Result of Shares Repurchase and Share Changes
November 4, 2025
Report for Q3 2025
October 29, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
October 15, 2025
Announcement on Obtaining Letter of Commitment for Special Loans for Stock Repurchase from Financial Institutions
September 30, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 29, 2025
Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit Concerning Shares Repurchase
September 25, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
September 12, 2025
Announcement on Convening the Semi-annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2025
September 8, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 7, 2025
Report on the Transfer Result of Shareholders' Inquiry and Indicative Announcement on Change in Equity of Shareholder with Reaching 5% Shares Exceeding Integer Multiple of 1%
July 22, 2025
Indicative Announcement on Pricing for Shareholder Inquiry Transfer
July 17, 2025
Shareholder's Inquiry Transfer Plan
July 16, 2025
Announcement on Change of Sponsor Representative for Continuous Supervision
June 9, 2025